UK markets closed

Poniard Pharmaceuticals, Inc. (PARD)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.00010.0000 (0.00%)
As of 03:13PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 434.76k
Enterprise value 434.76k
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)0.10
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.03

Trading information

Stock price history

Beta (5Y monthly) -35.48
52-week change 3-99.00%
S&P500 52-week change 322.38%
52-week high 30.0100
52-week low 30.0001
50-day moving average 30.0043
200-day moving average 30.0086

Share statistics

Avg vol (3-month) 32
Avg vol (10-day) 3N/A
Shares outstanding 51.5M
Implied shares outstanding 63B
Float 8N/A
% held by insiders 10.00%
% held by institutions 10.00%
Shares short (30 Nov 2011) 447.72k
Short ratio (30 Nov 2011) 42.56
Short % of float (30 Nov 2011) 44.11%
Short % of shares outstanding (30 Nov 2011) 43.18%
Shares short (prior month 14 Oct 2011) 43.73k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:40
Last split date 323 Nov 2011

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2010
Most-recent quarter (mrq)30 Sept 2011

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-46.03%
Return on equity (ttm)-210.37%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -13.04M
Net income avi to common (ttm)-16.23M
Diluted EPS (ttm)-0.0100
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.98M
Total cash per share (mrq)1.32
Total debt (mrq)1.64M
Total debt/equity (mrq)52.61%
Current ratio (mrq)0.76
Book value per share (mrq)2.08

Cash flow statement

Operating cash flow (ttm)-10.46M
Levered free cash flow (ttm)-4.53M